Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - capecitabine -

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - capecitabine -

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - capecitabine, quantity: 150 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; hypromellose; magnesium stearate; lactose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red - colon cancer ,capecitabine is indicated for the adjuvant treatment of patients with dukes? stage c and high-risk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer,capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer,capecitabine is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer,capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated ,capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - capecitabine, quantity: 500 mg - tablet, film coated - excipient ingredients: lactose; magnesium stearate; microcrystalline cellulose; hypromellose; croscarmellose sodium; titanium dioxide; purified talc; iron oxide yellow; iron oxide red - colon cancer ,capecitabine is indicated for the adjuvant treatment of patients with dukes? stage c and high-risk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer,capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer,capecitabine is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer,capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated ,capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Singapore - English - HSA (Health Sciences Authority)

intega pte ltd - capecitabine - tablet, film coated - capecitabine 150 mg

Singapore - English - HSA (Health Sciences Authority)

intega pte ltd - capecitabine - tablet, film coated - capecitabine 500 mg

Singapore - English - HSA (Health Sciences Authority)

zuellig pharma pte. ltd. - bevacizumab - injection, solution, concentrate - bevacizumab 25 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - capecitabine - film-coated tablet - 150 milligram(s) - pyrimidine analogues; capecitabine

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - capecitabine - film-coated tablet - 500 milligram(s) - pyrimidine analogues; capecitabine

Malta - English - Medicines Authority

alfred e. tiefembacher (gmbh &co. kg) van-der-smissen-straße 1, 22767 hamburg, germany - capecitabine - film-coated tablet - capecitabine 150 mg - antineoplastic agents